Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2018; 8(20):5562-5574. doi:10.7150/thno.26540 This issue Cite

Research Paper

Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure

Yi Li1,2,3,4*, Qiong Wu1*, Yujia Wang1,2,3, Chengxin Weng5, Yuting He1, Mengyu Gao1, Guang Yang6, Li Li1, Fei Chen1, Yujun Shi1, Bruce P. Amiot2, Scott L. Nyberg2,3, Ji Bao1✉, Hong Bu1✉

1. Laboratory of Pathology, Key Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China
2. Department of Surgery, Mayo Clinic, Rochester, MN, USA
3. William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA
4. Precision Medicine Key Laboratory, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China
5. West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan, China
6. Experimental Animal Center, West China Hospital, Sichuan University, Chengdu 610041, China
* The authors provided equal contribution to this work.

✉ Corresponding authors: Ji Bao, PhD. E-mail: baojiedu.cn. Hong Bu, MD. PhD. E-mail: hongbuedu.cn. Laboratory of Pathology, West China Hospital, Sichuan University, 37# Guoxue Road, Chengdu 610041, Sichuan Province, China. Tel.: +86-28-85164 More

Citation:
Li Y, Wu Q, Wang Y, Weng C, He Y, Gao M, Yang G, Li L, Chen F, Shi Y, Amiot BP, Nyberg SL, Bao J, Bu H. Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure. Theranostics 2018; 8(20):5562-5574. doi:10.7150/thno.26540. https://www.thno.org/v08p5562.htm
Other styles

File import instruction

Abstract

Graphic abstract

This study aims to evaluate the effectiveness and safety of the spheroid reservoir bioartificial liver (SRBAL) with porcine hepatocyte organoids in a preclinical nonhuman primate model of acute liver failure (ALF).

Methods: Thirty healthy rhesus monkeys were infused with α-amanitin and lipopolysaccharide and randomized into five groups (ALF alone control group; sham no-cell SRBAL treatment group; groups A, B and C with SRBAL treatment started at 12 h, 24 h and 36 h after induction of ALF, respectively). Animals were continuously treated with the SRBAL device for 6 h and followed for up to 336 h.

Results: Survival of ALF monkeys improved with hepatocyte SRBAL treatment compared to control groups. Blood ammonia and total bilirubin were lower, and albumin levels were higher in all hepatocyte SRBAL treatment groups. No evidence of porcine endogenous retrovirus was identified in monkey liver or blood after SRBAL treatment. Titers of monkey antibody (IgG, IgM) did not rise after SRBAL treatment. In survival cases, the proportion of necrotic and apoptotic hepatocytes was lower in SRBAL-treated groups, with earlier liver regeneration leading to recovery. Cytokines TNF-α, IL-6, IL-12, IL-1β, IL-8, IFN-γ and IL-2 were ameliorated by the SRBAL treatment, while levels of M-CSF; HGF, EGF and VEGF; IL-1RA and MIF rose on priming, proliferation and the late phase of liver regeneration.

Conclusions: The benefit of SRBAL therapy included preventive effects and therapeutic effects. SRBAL improved survival rate and prolonged median survival time in a nonhuman primate model of drug-induced ALF, and these benefits declined with a delay in the initiation of therapy. Improved survival and recovery of ALF monkeys was associated with a reduction in blood ammonia levels, inhibition of the pro-inflammatory response of ALF, and provided a microenvironment more suitable for regeneration of the injured liver.

Keywords: acute liver failure, bioartificial liver, hepatocyte, organoid, Macaca mulatta

Citation styles

APA
Li, Y., Wu, Q., Wang, Y., Weng, C., He, Y., Gao, M., Yang, G., Li, L., Chen, F., Shi, Y., Amiot, B.P., Nyberg, S.L., Bao, J., Bu, H. (2018). Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure. Theranostics, 8(20), 5562-5574. https://doi.org/10.7150/thno.26540.

ACS
Li, Y.; Wu, Q.; Wang, Y.; Weng, C.; He, Y.; Gao, M.; Yang, G.; Li, L.; Chen, F.; Shi, Y.; Amiot, B.P.; Nyberg, S.L.; Bao, J.; Bu, H. Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure. Theranostics 2018, 8 (20), 5562-5574. DOI: 10.7150/thno.26540.

NLM
Li Y, Wu Q, Wang Y, Weng C, He Y, Gao M, Yang G, Li L, Chen F, Shi Y, Amiot BP, Nyberg SL, Bao J, Bu H. Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure. Theranostics 2018; 8(20):5562-5574. doi:10.7150/thno.26540. https://www.thno.org/v08p5562.htm

CSE
Li Y, Wu Q, Wang Y, Weng C, He Y, Gao M, Yang G, Li L, Chen F, Shi Y, Amiot BP, Nyberg SL, Bao J, Bu H. 2018. Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure. Theranostics. 8(20):5562-5574.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use